{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-23-090888","form_type":"8-K","ticker":"ARMP","cik":"0000921114","company_name":"Armata Pharmaceuticals, Inc.","filed_at":"2023-08-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.033739+00:00","generated_at":"2026-06-11T13:40:47.225837+00:00","sec_items":["2.02","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Armata appoints Dr. Deborah Birx as CEO, secures $25M credit from Innoviva","bullets":["Dr. Deborah L. Birx appointed CEO and Board member; former Innoviva Board member and world-renowned healthcare leader.","New $25M credit agreement with Innoviva; existing convertible credit maturity extended to Jan 10, 2025.","Q2 loss from operations $(9.6)M; cash $12.5M at June 30, 2023; 36.1M shares outstanding.","Phase 2 inhaled AP-PA02 in NCFB enrolling; AP-SA02 bacteremia study advancing to Phase 2a in 3Q23.","$16.3M total grant funding from DoD/MTEC for AP-SA02 program."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-23-090888","json":"https://secwatch.observer/filing/0001104659-23-090888.json","markdown":"https://secwatch.observer/filing/0001104659-23-090888.md","text":"https://secwatch.observer/filing/0001104659-23-090888.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/921114/000110465923090888/0001104659-23-090888-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/921114/000110465923090888/tm2323624d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T13:40:47.225837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"22ababbff3372236cd3b8c085d74cfec287ea48a","claim":"Armata Pharmaceuticals, Inc. reported financial results for the quarter ended June 30, 2023.","evidence_excerpt":"announced its financial results for the quarter ended June 30, 2023","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/921114/000110465923090888/0001104659-23-090888-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended June 30, 2023"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}